Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02507375 | A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 17 | Hoffmann-La RocheINDUSTRY | 3 | Oct 16, 2015 | clinicaltrials |
| NCT00993499 | Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib | completed | Phase 1 | 44 | Boehringer IngelheimINDUSTRY | 1 |
| Oct 7, 2015 |
| clinicaltrials |
| NCT02134886 | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection | terminated | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01004419 | Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | University of Wisconsin, MadisonOTHER | 0 | Oct 2, 2015 | clinicaltrials |
| NCT01090011 | Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer | completed | Phase 1 | 171 | Boehringer IngelheimINDUSTRY | 2 | Oct 2, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01193881 | RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01628471 | MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 20 | Uman PharmaINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00178256 | Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer | completed | Phase 1 / Phase 2 | 41 | University of RochesterOTHER | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00704392 | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors | withdrawn | Phase 1 | 0 | ExelixisINDUSTRY | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01553656 | Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer | completed | Phase 1 | 85 | ExelixisINDUSTRY | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00985998 | Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01219348 | IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.(IDOvaccine) | completed | Phase 1 | 14 | Inge Marie SvaneOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT00907179 | Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 12 | University of PittsburghOTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00327288 | Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients | completed | Phase 1 | 34 | AmpliMed CorporationINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00378404 | Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC | terminated | Phase 1 | 10 | Susanne ArnoldOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01602289 | A Study of LY2875358 in Japanese Participants With Advanced Cancer | completed | Phase 1 | 17 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01222572 | Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT02175381 | Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 69 | Hellenic Oncology Research GroupOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00934076 | Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | May 8, 2015 | clinicaltrials |
| NCT00743379 | Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 71 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00832819 | E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 28 | Eisai Co., Ltd.INDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00707252 | Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 11 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT01772732 | Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2015 | clinicaltrials |
| NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 203 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 8, 2015 | clinicaltrials |
| NCT01714037 | A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC](HALO) | terminated | Phase 1 | 82 | Debiopharm International SAINDUSTRY | 3 | Apr 8, 2015 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT02066870 | Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI | unknown | Phase 1 | 9 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | terminated | Phase 1 / Phase 2 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 6, 2015 | clinicaltrials |
| NCT01048983 | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 5, 2015 | clinicaltrials |
| NCT00441337 | A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies(MDX1106-01) | completed | Phase 1 | 39 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 20, 2015 | clinicaltrials |
| NCT01683682 | An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)(VENUS-2) | completed | Phase 1 | 8 | Aktion Bronchialkarzinom e.V.OTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | terminated | Phase 1 | 54 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT00975767 | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | terminated | Phase 1 | 126 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01700400 | Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | completed | Phase 1 | 13 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01799161 | Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Eckhard PodackOTHER | 0 | Nov 17, 2014 | clinicaltrials |
| NCT01427946 | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00108186 | Celecoxib Treatment for Lung Cancer | withdrawn | Phase 1 | 0 | US Department of Veterans AffairsFED | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00088959 | Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2014 | clinicaltrials |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | terminated | Phase 1 / Phase 2 | 43 | Duke UniversityOTHER | 0 | Sep 15, 2014 | clinicaltrials |
| NCT00056537 | ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer | completed | Phase 1 | 44 | Active Biotech ABINDUSTRY | 3 | Aug 27, 2014 | clinicaltrials |
| NCT00132379 | ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 13 | Active Biotech ABINDUSTRY | 3 | Aug 27, 2014 | clinicaltrials |
| NCT02211833 | Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer | completed | Phase 1 | 41 | Boehringer IngelheimINDUSTRY | 0 | Aug 8, 2014 | clinicaltrials |
| NCT02209727 | Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 9 | Boehringer IngelheimINDUSTRY | 0 | Aug 6, 2014 | clinicaltrials |
| NCT01668823 | Photodynamic Therapy in Treating Patients With Lung Cancer | completed | Phase 1 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2014 | clinicaltrials |
| NCT00787852 | A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 11 | Brown UniversityOTHER | 1 | Jul 30, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Oct 16, 2015source: clinicaltrials